Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Summary

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.  The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Oncology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Fragile X Syndrome, Head And Neck Cancer, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury. 

Furthermore, this report also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview 6
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles 17
Bryostatin-1 - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
VMD-1201 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
VMD-2202 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products 29
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products 30
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones 31
Featured News & Press Releases 31
Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 31
Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting 32
May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease 32
Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017 33
Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia 34
Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease 34
Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead 35
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes 36
Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease 36
Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 37
Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer's Disease 37
Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer's Disease 38
Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer's Disease 38
Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference 39
Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 16
Dormant Projects, H2 2017 29
Discontinued Products, H2 2017 30